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Abstract
Drug-induced cardiovascular failure is an acute condition that is
associated with significant healthcare consequences. Antidotes
and supportive treatments are the initial measures to manage
cardiotoxicity, but if severe drug-induced cardiotoxicity develops,
usually as cardiovascular shock or cardiac arrest, then circulatory
assistance may have an important role in the therapeutic algorithm.
A number of circulatory assistance techniques have been
increasingly employed to treat severe drug-induced cardiotoxicity.
These include extracorporeal membrane oxygenation, intra-aortic
balloon pumping and standard cardiopulmonary bypass. Recently,
extracorporeal life support (ECLS) has been developed to provide
percutaneous cardiopulmonary support peripherally without the
need for sternotomy. ECLS can provide successful treatment of
severe drug-induced cardiotoxicity in selected cases. This
technique may be associated with complications of limb ischaemia,
haemorrhage and embolism. An increased consideration of ECLS
within the context of rigorous clinical studies and strong evidence
can add to its future use for severe drug-induced cardiotoxicity.
In their recent study, Daubin and colleagues [1] highlight the
management of drug-induced cardiotoxicity. Cardiovascular
failure as a result of drug poisoning is an acute condition that
is associated with significant healthcare consequences.
Although cardiovascular drugs account for 3.5% of all drug
poisoning cases, their mortality impact can be dispropor-
tionately high (16.38% of deaths) [2]. Of these drugs, those
with membrane stabilising activity impede depolarisation and
are associated with increased mortality [3]. There are several
modes of severe cardiotoxicity presentation, including persis-
tent hypotension, cardiogenic shock, atrio-ventricular block,
asystole, pulseless ventricular tachycardia and ventricular
fibrillation.
Antidotes and supportive treatments are the initial measures
to manage cardiotoxicity, but if severe drug-induced cardio-
toxicity develops, usually as cardiovascular shock or cardiac
arrest, then circulatory assistance may have an important role
in the therapeutic algorithm [4]. This provides temporal
circulatory support to the vital organs whilst unloading the
myocardium to encourage myocardial recovery. A number of
circulatory assistance techniques have been increasingly
employed to treat severe drug-induced cardiotoxicity. These
include extracorporeal membrane oxygenation, where a
venous-venous circuit can treat hypoxaemia in the absence of
mechanical circulatory support. Intra-aortic balloon pumping
can be used percutaneously to increase cardiac output whilst
decreasing myocardial oxygen demand through a counter-
pulsating aortic balloon. In the past, standard cardio-
pulmonary bypass was used to provide definitive oxygenation
and mechanical support, although it requires full sternotomy.
Recently, however, the technique of extracorporeal life
support (ECLS) has been developed to provide percu-
taneous cardiopulmonary support peripherally without the
need for sternotomy [5].
Daubin and colleagues report a single-institution, retrospec-
tive review of 17 adult cardiotoxic drug-overdose patients
who received ECLS for prolonged cardiac arrest or refractory
shock [1]. Their 10-year experience reflects an increased
familiarity of performing this procedure compared to other
techniques of cardiac assistance in the setting of drug-
induced cardiotoxicity. Despite 59% of patients suffering
cardiac toxicity as a result of hazardous drugs with membrane
stabilizing activity, they quote favourable results of 76% of
individuals being discharged to hospital without sequelae.
This is maintained with relatively long ECLS duration times,
with a mean of 4.5 days compared to less than 24 hours for
the majority of cases requiring cardiopulmonary bypass in
previous reports [6].
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The timing of ECLS commencement after hospital admission
reported by Daubin and colleagues was over 15 hours in four
individuals with refractory shock. Although this is much longer
than equivalent time-to-cardiopulmonary bypass in reported
series, the patients had a satisfactory outcome. These longer
times to treatment may reflect the delayed cardiotoxic
presentation of some cardiotropic drugs seen in overdosed
patients [7,8].
Daubin and colleagues included patients with refractory shock
and cardiac arrest in their cohort and it is important to keep in
mind that these conditions may be caused by different
pathologies. In 2007 Megarbane and colleagues [9] presented
the outcomes of 12 patients undergoing ECLS for refractory
cardiac arrest after cardiotoxic poisoning. In this prospective
study only 25% of patients survived ICU discharge after ECLS.
This comparatively poor outcome needs further investigation
and may be related to shorter mean ECLS times of 2.3 days
versus 4.5 days for Daubin and colleagues.
ECLS can be associated with a number of cannulation-
related complications and Daubin and colleagues report their
experience of limb ischaemia, haemorrhage, femoral
thrombus and inferior vena caval thrombus. This is consistent
with other studies of emergency extracorporeal circulation
[5,10] despite the use of percutaneous Seldinger techniques
and protective manoeuvres such as additional limb perfusion.
The high rate of vascular complications, however, requires
consideration, particularly as Megarbane and colleagues [9]
quote no reports of limb ischaemia. This again may be related
to the shorter duration of ECLS, but also requires the assess-
ment of anatomical cannulation site, technique, equipment
and hospital setting. One case required left atrial decom-
pression (via balloon-septostomy); although this has been
previously reported for the ECLS procedure [5], it has not
previously been described in the context of poisoning.
As a result of the finding that all ECLS survivors were
discharged without significant cardio-vascular or neurological
sequelae, the authors comment that ECLS is a safe and
efficient therapeutic option for critically ill poisoned patients.
In the authors’ experience ECLS was applicable in a variety of
hospital settings, including the ICU, emergency department
and operating theatres.
There are a number of important questions to be addressed
in analyzing this experience. First, what are the indications of
ECLS and what are the benefits compared to other methods
of circulatory assistance? Should the choice of ECLS
depend on institution preference or depend on national/
international guidelines? This requires clear outcome data
and stronger levels of evidence to guide management
decisions. Secondly, which vessels should be cannulated in
each patient to decrease complications and in which hospital
locations should these procedures be performed? Thirdly,
which healthcare professionals should decide on the
appropriateness and technique of ECLS cannulation and how
much training is necessary to ensure that practitioners can
perform this procedure reliably and safely?
The future use of ECLS in treating cardiotoxic drug overdose
patients depends on identifying the patients who will benefit
most from this procedure whilst making the available
technology safer and simpler to use. This will require larger
clinical studies to stratify patients according to risk and will
entail both improved techniques and equipment. Surgeons
will require adequate training on animal models and advanced
simulators to be more confident with emergency percu-
taneous or cut-down techniques of vascular access. Cardio-
pulmonary bypass equipment for cannulation will require
enhancement to minimise embolism and haemorrhage. Impor-
tantly, however, there is strong need for close collaboration
and communication between intensivists, surgeons, perfu-
sionists and toxicologists. Daubin and colleagues demon-
strated that ECLS can successfully treat cardiotoxic drug-
induced shock and arrest. An increased consideration of
ECLS within the context of rigorous clinical studies and
strong evidence can add to its future use for severe drug-
induced cardiotoxicity.
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